Clinical Cancer Research, Vol 2, Issue 7 1199-1206, Copyright © 1996 by American Association for Cancer Research

ARTICLES

The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients

S Oesterreich, SG Hilsenbeck, DR Ciocca, DC Allred, GM Clark, GC Chamness, CK Osborne and SA Fuqua
Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7884, USA.

Heat shock protein 27 (hsp27) belongs to the family of heat shock proteins and is thought to be involved in thermotolerance, cell proliferation, drug resistance, and chaperone processes. The aim of this study was to investigate whether hsp27 levels are correlated with clinical outcome in axillary lymph node-negative breast cancer patients. We describe a Western blot study measuring hsp27 levels in 425 patients and an immunohistochemistry (IHC) study analyzing 788 patients. Results obtained by both methods were concordant. Univariate survival analysis was performed considering hsp27 either as an optimally dichotomized variable or as a continuous variable. Additional data include age at biopsy, tumor size, estrogen receptor (ER) and progesterone receptor status, tumor ploidy and percentage of cells in S phase, and adjuvant therapy. hsp27 levels correlated positively with ER status (P = 0.0001 in Western blot and IHC study), progesterone receptor status (P = 0.0001 in Western blot and IHC study), and aneuploidy (Western blot study, P = 0.0012; IHC study, P = 0.0004) but not with tumor size (Western blot study, P = 0.69; IHC, P = 0.53) or S phase (Western blot study, P = 0.19; IHC study, P = 0.38). Overall, there was no relationship between hsp27 expression and disease-free survival (Western blot study, P = 0.70/0.54; IHC, P = 0.47/0.30) or overall survival (Western blot study, P = 0.16/0.15; IHC, P = 0.46/0.78). Exploratory subset analyses defined by ER status and use of adjuvant treatment indicated that in ER+/untreated patients, high hsp27 levels correlated modestly with shorter disease-free survival (Western blot, P = 0.04/0.04; IHC, P = 0.11/0. 03). hsp27 is not a useful prognostic marker for the clinic in axillary lymph node-negative patients. However, the finding of modest prognostic value of hsp27 in the subgroup of ER+/untreated patients raises new questions about the biological function of hsp27 in breast cancer.

This article has been cited by other articles:

				M. Kamada, A. So, M. Muramaki, P. Rocchi, E. Beraldi, and M. Gleave Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 299 - 308. [Abstract] [Full Text] [PDF]

				H. Chen, M. Hewison, B. Hu, M. Sharma, Z. Sun, and J. S. Adams An Hsp27-related, Dominant-negative-acting Intracellular Estradiol-binding Protein J. Biol. Chem., July 16, 2004; 279(29): 29944 - 29951. [Abstract] [Full Text] [PDF]

				A. Parcellier, E. Schmitt, S. Gurbuxani, D. Seigneurin-Berny, A. Pance, A. Chantome, S. Plenchette, S. Khochbin, E. Solary, and C. Garrido HSP27 Is a Ubiquitin-Binding Protein Involved in I-{kappa}B{alpha} Proteasomal Degradation Mol. Cell. Biol., August 15, 2003; 23(16): 5790 - 5802. [Abstract] [Full Text] [PDF]